Table 1. Baseline Characteristics of Participants.
Characteristic | No. (%) | |
---|---|---|
MEAL Intervention Group (n = 226) | Control Group (n = 217) | |
Age, y | ||
Mean (SD) | 63.7 (6.5) | 63.5 (6.6) |
Median (IQR) | 64.0 (59.0-68.0) | 64.0 (59.0-68.0) |
<70 y | 186 (82.3) | 173 (79.7) |
Race and ethnicity | n = 226 | n = 216 |
Non-Hispanic white | 186 (82.3) | 171 (78.8) |
Non-Hispanic black or African American | 24 (10.6) | 26 (12.0) |
Hispanic or Latino | 9 (4.0) | 7 (3.2) |
Asian | 6 (2.7) | 9 (4.1) |
More than 1 race/ethnicity | 0 (0.0) | 2 (0.9) |
Native Hawaiian or Pacific Islander | 0 (0.0) | 1 (0.5) |
American Indian or Alaska Native | 1 (0.4) | 0 (0.0) |
Region | ||
West | 85 (37.6) | 78 (35.9) |
Northeast | 56 (24.8) | 48 (22.1) |
South | 43 (19.0) | 39 (18.0) |
Midwest | 42 (18.6) | 52 (24.0) |
Body mass indexa | n = 55 | n = 53 |
Mean (SD) | 28.7 (5.9) | 28.3 (3.7) |
Median (IQR) | 27.5 (24.5-31.0) | 28.4 (26.0-30.8) |
Prostate biopsy within 12 mob | 192 (85.0) | 183 (84.3) |
Tumor stage | n = 225 | n = 217 |
cT1a | 4 (1.8) | 1 (0.5) |
cT1b | 1 (0.4) | 2 (0.9) |
cT1c | 197 (87.6) | 187 (86.2) |
cT2a | 23 (10.2) | 27 (12.4) |
Serum PSA level, ng/mL | n = 224 | n = 217 |
0-2.5 | 25 (11.2) | 30 (13.8) |
>2.5-5 | 99 (44.2) | 98 (45.2) |
Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.
Calculated as weight in kilograms divided by height in meters squared.
The remainder of participants underwent prostate biopsy within 13 to 24 months.